Topiramate for alcoholism treatment: novel pharmacogenetic evidence for the journey to personalized medicine?

Topiramate Treatment for Heavy Drinkers: Moderation by aGRIK1Polymorphism

(2014) Henry R. Kranzler et al.   AMERICAN JOURNAL OF PSYCHIATRY

Results from clinical trials of a selective ionotropic glutamate receptor 5 (iGluR5) antagonist, LY5454694 tosylate, in 2 chronic pain conditions

(2014) Amy S. Chappell et al.   PAIN

Safety, tolerability, pharmacokinetics, and effects on human experimental pain of the selective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 in healthy volunteers

(2014) Karin L. Petersen et al.   PAIN

Use of Novel Technology-Based Techniques to Improve Alcohol-Related Outcomes in Clinical Trials

(2013) Eugenia M. Gurvich et al.   ALCOHOL AND ALCOHOLISM

Determination of Genotype Combinations That Can Predict the Outcome of the Treatment of Alcohol Dependence Using the 5-HT3Antagonist Ondansetron

(2013) Bankole A. Johnson et al.   AMERICAN JOURNAL OF PSYCHIATRY

Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: A 12-week, randomized, placebo-controlled trial

(2013) Surinporn Likhitsathian et al.   DRUG AND ALCOHOL DEPENDENCE

Variation inOPRM1moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment

(2012) Henry R. Kranzler et al.   ADDICTION BIOLOGY

Pharmacogenetic Approach at the Serotonin Transporter Gene as a Method of Reducing the Severity of Alcohol Drinking

(2011) Bankole A. Johnson et al.   AMERICAN JOURNAL OF PSYCHIATRY

Selective Kainate Receptor (GluK1) Ligands Structurally Based upon 1H-Cyclopentapyrimidin-2,4(1H,3H)-dione: Synthesis, Molecular Modeling, and Pharmacological and Biostructural Characterization

(2011) Raminta Venskutonytė et al.   JOURNAL OF MEDICINAL CHEMISTRY

Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients

(2010) Bankole A. Johnson et al.   CURRENT PHARMACEUTICAL DESIGN

Acamprosate: How, Where, and for Whom Does it Work? Mechanism of Action, Treatment Targets, and Individualized Therapy

(2010) Falk Kiefer et al.   CURRENT PHARMACEUTICAL DESIGN

A Double-Blind, Randomized Trial of Sertraline for Alcohol Dependence

(2010) Henry R. Kranzler et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate

(2010) F Kiefer et al.   PHARMACOGENOMICS JOURNAL

Association of Markers in the 3′ Region of the GluR5 Kainate Receptor Subunit Gene to Alcohol Dependence

(2009) Henry R. Kranzler et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Suppression of Alcohol Preference by Naltrexone in the Rhesus Macaque: A Critical Role of Genetic Variation at the μ-Opioid Receptor Gene Locus

(2009) Christina S. Barr et al.   BIOLOGICAL PSYCHIATRY

A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.

(2009) Lara A. Ray et al.   EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY

Typologies of Alcohol Dependence. From Jellinek to Genetics and Beyond

(2009) Lorenzo Leggio et al.   NEUROPSYCHOLOGY REVIEW

Effects of Topiramate on Urge to Drink and the Subjective Effects of Alcohol: A Preliminary Laboratory Study

(2008) Robert Miranda Jr et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

A Within-Group Design of Nontreatment Seeking 5-HTTLPR Genotyped Alcohol-Dependent Subjects Receiving Ondansetron and Sertraline

(2008) George A. Kenna et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

An Evaluation of μ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence

(2008) Raymond F. Anton et al.   ARCHIVES OF GENERAL PSYCHIATRY